Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders.
Cimeio Therapeutics has raised $50.0M in total funding. The most recent round was Series A. The last funding was announced in April 2022.
Cimeio Therapeutics's investors include Versant Ventures.
Cimeio Therapeutics is headquartered in Basel, Switzerland.
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders.
Cimeio Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cimeio Therapeutics — Funding & Investors." VCBacked, April 13, 2022, https://www.vcbacked.co/company/cimeio-therapeutics. Accessed October 7, 2026.
VCBacked. (2022). Cimeio Therapeutics — Funding & Investors. Retrieved October 7, 2026, from https://www.vcbacked.co/company/cimeio-therapeutics
{{cite web |title=Cimeio Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/cimeio-therapeutics |website=VCBacked |access-date=October 7, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated